FDA Approves Giredestrant Plus Everolimus for Advanced Breast Cancer With ER-Positive ESR1 Mutations

FDA Approves Giredestrant Plus Everolimus for Advanced Breast Cancer With ER-Positive ESR1 Mutations

The FDA has approved giredestrant plus everolimus for adults with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an ESR1 mutation detected by an FDA-authorized test. Roche and Genentech announced the decision.

The approval covers two routes to eligibility based on when the disease returned or progressed. It includes patients whose breast cancer recurred during or after completion of endocrine-based adjuvant therapy, as well as patients whose disease progressed on at least one endocrine-based regimen in the metastatic setting.

In both cases, the ESR1 test result determines whether the tumor meets the biomarker requirement for the all-oral combination.

evERA Compared 2 Endocrine Combinations After CDK4/6 Inhibition

The phase III evERA Breast Cancer trial was a randomized, open-label, multicenter study in patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer. Participants had previously received a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor and endocrine therapy in the adjuvant or advanced disease setting. Both study arms received everolimus. The trial tested whether pairing it with giredestrant improved outcomes compared with pairing it with standard endocrine therapy.

The trial had two co-primary endpoints, both based on investigator-assessed progression-free survival (PFS). One evaluated all randomized patients in the intention-to-treat population, and the other evaluated patients with ESR1 mutations. PFS was measured from randomization to disease progression or death from any cause.

Progression-free survival in the ESR1-mutated population. Giredestrant plus everolimus reduced the risk of disease progression or death by 62% compared with standard endocrine therapy plus everolimus. The stratified hazard ratio was 0.38 (95% CI, 0.27–0.54, p < 0.0001).
Key secondary endpoints. The study also assessed overall survival, objective response rate, duration of response, clinical benefit rate, and safety.

The announcements highlighted the PFS result in the ESR1-mutated population, which corresponds to the biomarker specified in the approved indication. The evERA results were published in The New England Journal of Medicine.

Erica Mayer, Director of Breast Cancer Clinical Research at Dana-Farber Cancer Institute, said:

“Patients with advanced breast cancer progressing on endocrine therapies often face difficult choices and deteriorating quality of life as options narrow.”

How Giredestrant and Everolimus Address Endocrine Resistance

Roche and Genentech reported that up to 40% of patients with hormone receptor-positive metastatic breast cancer develop ESR1 mutations that can drive resistance to endocrine therapy. Giredestrant is an oral selective estrogen receptor degrader (SERD). It blocks estrogen from binding to the receptor and promotes degradation of the receptor protein, reducing estrogen receptor signaling.

Everolimus inhibits mTOR, a component of the PI3K/AKT/mTOR signaling pathway. The companies identified activation of this pathway, alongside continued dependence on estrogen receptor signaling, as one mechanism of resistance after treatment with a CDK4/6 inhibitor and endocrine therapy. The combination pairs estrogen receptor degradation with mTOR inhibition. Roche announcement

Safety Findings and Adverse Reactions

Genentech identified bradycardia as a potentially serious adverse effect of giredestrant. Its safety information calls for more frequent heart rate monitoring in patients with a history of bradycardia or those taking certain cardiac medications.

Common adverse reactions listed for giredestrant plus everolimus included stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, lung or breathing problems, and nausea. Common laboratory abnormalities included decreases in red blood cell, white blood cell, and platelet counts, elevations in AST, ALT, and creatinine, and decreases in calcium, potassium, and sodium levels. Genentech safety information

lidERA Supports a Separate FDA Review in Early Breast Cancer

The adjuvant application covers adults with ER-positive, HER2-negative stage I, II, or III breast cancer at intermediate to high risk of recurrence. It is based on the phase III lidERA Breast Cancer trial, which compared giredestrant with standard endocrine therapy in the adjuvant setting. The FDA accepted the New Drug Application under Priority Review.

The two phase III trials address different treatment decisions. evERA evaluated whether adding giredestrant to an everolimus-based regimen could extend PFS in previously treated advanced disease. lidERA evaluated giredestrant as adjuvant endocrine therapy in early disease. Roche and Genentech said an adjuvant approval would make giredestrant the first SERD approved for both adjuvant and advanced ER-positive breast cancer.

Genentech expects giredestrant to become available in the United States in the weeks following the advanced breast cancer approval. The FDA has set November 30, 2026, as its target action date for the adjuvant application. Phase III readouts also remain pending for pionERA and heredERA in advanced breast cancer and for novERA and kalitERA, which are evaluating treatment adherence, tolerability, and patient-reported outcomes in early breast cancer.

You can also read: evERA Breast Cancer: Giredestrant Plus Everolimus Extends PFS After CDK4/6 Inhibitor Resistance.

FDA